| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
37,013 |
31,623 |
$6.01M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
24,156 |
21,280 |
$4.01M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
15,728 |
13,388 |
$2.52M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
902 |
591 |
$1.33M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
16,606 |
13,764 |
$1.18M |
| 71046 |
Radiologic examination, chest; 2 views |
7,103 |
6,128 |
$1.07M |
| 71045 |
Radiologic examination, chest; single view |
6,971 |
5,885 |
$992K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
7,510 |
6,805 |
$907K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
776 |
589 |
$795K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
10,975 |
9,467 |
$729K |
| 64483 |
|
545 |
420 |
$502K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
4,206 |
3,741 |
$300K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
574 |
149 |
$298K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
2,088 |
673 |
$291K |
| 80053 |
Comprehensive metabolic panel |
36,398 |
29,376 |
$224K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
44,777 |
36,314 |
$199K |
| 36415 |
Collection of venous blood by venipuncture |
81,609 |
62,077 |
$183K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,406 |
329 |
$153K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
366 |
143 |
$143K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
1,257 |
417 |
$117K |
| 87631 |
|
1,606 |
1,497 |
$114K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,302 |
1,660 |
$98K |
| 81025 |
|
17,549 |
15,145 |
$89K |
| 70450 |
Computed tomography, head or brain; without contrast material |
688 |
549 |
$85K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
207 |
159 |
$77K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
469 |
418 |
$77K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
2,441 |
2,166 |
$72K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
2,415 |
2,143 |
$71K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
162 |
99 |
$68K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,301 |
2,529 |
$66K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,898 |
1,591 |
$64K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
2,732 |
2,459 |
$60K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
283 |
226 |
$60K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
239 |
201 |
$56K |
| 84484 |
|
5,674 |
4,281 |
$56K |
| 81001 |
|
24,260 |
20,407 |
$47K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
4,374 |
3,677 |
$42K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
15 |
12 |
$38K |
| 88142 |
|
3,110 |
2,834 |
$32K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,199 |
1,088 |
$32K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
171 |
149 |
$26K |
| 83690 |
|
6,075 |
5,030 |
$23K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,084 |
1,840 |
$22K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,193 |
683 |
$21K |
| 80061 |
Lipid panel |
2,282 |
2,032 |
$21K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
841 |
778 |
$19K |
| 83735 |
|
4,676 |
3,763 |
$19K |
| 80050 |
General health panel |
119 |
110 |
$18K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,043 |
940 |
$17K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
124 |
118 |
$17K |
| 99220 |
|
178 |
26 |
$11K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
62 |
55 |
$11K |
| 85027 |
|
2,047 |
1,633 |
$10K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,495 |
1,350 |
$10K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
16 |
16 |
$9K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,572 |
1,731 |
$9K |
| 31579 |
|
13 |
12 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,328 |
1,065 |
$9K |
| 86780 |
|
763 |
695 |
$9K |
| 84439 |
|
1,286 |
1,165 |
$8K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,445 |
1,982 |
$8K |
| 92567 |
|
204 |
180 |
$8K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
15 |
12 |
$8K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,902 |
1,333 |
$7K |
| 76818 |
|
35 |
26 |
$5K |
| 86769 |
|
196 |
149 |
$4K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
96 |
50 |
$4K |
| 87581 |
|
94 |
49 |
$4K |
| 87486 |
|
94 |
49 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
238 |
133 |
$4K |
| 86140 |
|
1,165 |
1,035 |
$4K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
99 |
27 |
$3K |
| 93296 |
|
13 |
12 |
$3K |
| 83655 |
|
227 |
179 |
$3K |
| 85730 |
|
1,131 |
836 |
$3K |
| 82607 |
|
307 |
266 |
$3K |
| 76536 |
|
13 |
13 |
$3K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
228 |
131 |
$3K |
| 85610 |
|
1,443 |
1,003 |
$3K |
| 80076 |
|
553 |
503 |
$3K |
| 82947 |
|
836 |
647 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
175 |
80 |
$2K |
| 96376 |
|
1,001 |
360 |
$2K |
| 92557 |
|
13 |
13 |
$2K |
| 84550 |
|
614 |
548 |
$2K |
| 85652 |
|
1,149 |
1,026 |
$2K |
| 87807 |
|
127 |
56 |
$2K |
| 83880 |
|
66 |
61 |
$2K |
| 84481 |
|
213 |
201 |
$2K |
| 92588 |
|
27 |
13 |
$2K |
| 82565 |
|
460 |
420 |
$1K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
130 |
112 |
$1K |
| 87150 |
|
44 |
40 |
$1K |
| 93017 |
|
16 |
16 |
$950.90 |
| 87641 |
|
53 |
42 |
$854.15 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
39 |
38 |
$781.72 |
| 87640 |
|
52 |
41 |
$750.98 |
| 86850 |
|
205 |
164 |
$608.58 |
| 87081 |
|
49 |
32 |
$388.57 |
| 84207 |
|
57 |
41 |
$371.55 |
| 87070 |
|
43 |
40 |
$370.06 |
| 86900 |
|
205 |
164 |
$347.23 |
| 86901 |
|
205 |
164 |
$341.25 |
| 88143 |
|
13 |
13 |
$276.48 |
| 87340 |
|
27 |
26 |
$189.30 |
| 82746 |
|
36 |
25 |
$158.49 |
| 84436 |
|
40 |
36 |
$158.12 |
| 86803 |
|
12 |
12 |
$146.98 |
| 86762 |
|
12 |
12 |
$142.47 |
| 84702 |
|
14 |
13 |
$135.45 |
| 86200 |
|
19 |
13 |
$123.85 |
| 86765 |
|
12 |
12 |
$114.62 |
| 86038 |
|
16 |
12 |
$113.79 |
| J2785 |
Injection, regadenoson, 0.1 mg |
13 |
13 |
$105.00 |
| 82550 |
|
49 |
38 |
$94.70 |
| 85007 |
|
19 |
14 |
$78.09 |
| 84703 |
|
17 |
15 |
$72.90 |
| 82962 |
|
96 |
79 |
$68.02 |
| 86431 |
|
18 |
12 |
$43.99 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,118 |
4,195 |
$17.97 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,536 |
1,002 |
$1.04 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,157 |
878 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
2,261 |
1,330 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
907 |
631 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
228 |
173 |
$0.00 |
| 88342 |
|
16 |
12 |
$0.00 |
| 85379 |
|
14 |
12 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
16 |
16 |
$0.00 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
59 |
49 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,031 |
760 |
$0.00 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
717 |
523 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
317 |
85 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
51 |
39 |
$0.00 |
| 77003 |
|
771 |
565 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
203 |
166 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
68 |
26 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
157 |
119 |
$0.00 |